Risk of cardiac valvulopathy with use of bisphosphonates: a population-based, multi-country case-control study.

ABSTRACT:

Unlabelled

Analyses of healthcare data from 30 million individuals in three countries showed that current use of bisphosphonates may be associated with a small increased risk of cardiac valvulopathy (vs. those not exposed within the previous year), although confounding cannot be entirely ruled out. The observed tendency for decreased valvulopathy risk with cumulative duration of bisphosphonate use >6 months may even indicate a protective effect with prolonged use. Further studies are still needed to evaluate whether bisphosphonates increase or decrease the risk of valvulopathy.

Introduction

A signal of cardiac valve disorders with use of bisphosphonates was identified in the literature and EudraVigilance database, which contains reports of suspected adverse drug reactions fr

SUBMITTER: Coloma PM 

PROVIDER: S-EPMC4839043 | biostudies-literature | 2016 May

REPOSITORIES: biostudies-literature